Prospect

Principal Investigator:
Gillian Carey

Studying atypical parkinsonian disorders, specifically Progressive Supranuclear Palsy (PSP), Multiple System Atrophy, Cortico-Basal syndrome (CBS) and related conditions. Its aim is to understand more about the causes of these diseases through the collection of information on genetic (inherited) make-up and environmental exposures. 15 participants have been recruited to date at St Peter’s Hospital. Participants are asked to complete a one-off questionnaire and are asked to donate a blood or saliva sample. Participants nominate an informant, usually a close relative, who can share medical information about the participant with the research team and complete questionnaires. This study is sponsored by University College London.

First Steps

Principal Investigator:
Dr Jan Coebergh

First Steps has been designed to provide support and advice for people recently diagnosed with Parkinson’s disease (within the last 12 months). Everyone who takes part in the study will have the opportunity to take part in the First Steps program. However the research has started before the First Steps program is available in Surrey. As the program is a new initiative, this research is being conducted in order to evaluate and inform its development. Participants are required to complete 3 questionnaires by telephone contact over 6 months. Participants are asked questions about themselves (such as age, ethnicity, work status) and things that may be affected by Parkinson’s (such as general health, ability to perform daily activities and how much activity is performed). St Peter’s Hospital is acting as a PIC (Participant Identification Centre) for this study and Oxford Brookes University are conducting the telephone interviews.

PD Stat

Principal Investigator:
Dr Jan Coebergh

The aim of this study is to determine whether the cholesterol-lowering drug, simvastatin, has potential as a neuroprotective therapy in Parkinson’s disease. It is a randomised, double-blind, placebo controlled trial. We currently have 17 participants in follow -up. Participants are enrolled in the study for 27 months and undergo a series of clinic visits and telephone calls. Participants attend clinic in the PD drug naïve state on 4 occasions over the 27 month period and their symptoms are assessed pre and post their PD medication. This study is sponsored by Plymouth Hospitals NHS Trust and is being run over 23 hospital sites. St Peter’s is proud to be the 4th highest recruiting site.

Proband: Tracking Parkinson’s

Principal Investigator:
Dr Z Dhakam

This study involves people with Parkinson’s disease and their families and is being conducted across a network of clinics in the UK (72 sites). The primary objective is to define and explain variation in the clinical phenotype of PD in relation to genotypic variation. Secondary objectives are to support additional studies exploring genetic, serum and imaging biomarkers for the diagnosis, stratification and progression of PD. The clinical features of the Parkinson condition is recorded over time. Blood samples are taken for gene tests and for longer term storage to support future research. We currently have 17 participants in follow-up and 5 relatives of people with Parkinson’s who are acting as controls. This study is sponsored by the Institute of Neurological Sciences, Southern General Hospital Glasgow.

PD Manager

Principal Investigator:
Dr Jan Coebergh

This study, sponsored by the University of Surrey, explores new technologies for monitoring Parkinson’s symptoms in real time and provides a continuous record for health professionals. The PD Manager system constitutes a wristband, an insole to be worn in shoes and a smartphone. The purpose of the study is to find out if people with Parkinson’s and their family members find the devices acceptable and easy to use. Doctors are also asked if they find the information that is generated through PD Manager is helpful to them in deciding on treatment modification. Participants are randomised either to receive the PD manager system or to complete a symptom diary for a 2 week period. A post- intervention consultation with their doctor is then performed. We have recruited 10 participants to this study.

DexEnceph

Principal Investigator:
Dr Khaled Adbel-Aziz

A pragmatic, randomised, controlled, observer blind trial comparing clinical outcomes in adults who receive dexamethasone alongside standard treatment versus standard treatment alone for Herpes Simplex Virus encephalitis.